NUVL
Price
$107.17
Change
+$19.17 (+21.78%)
Updated
Feb 3 closing price
Capitalization
8.32B
28 days until earnings call
Intraday BUY SELL Signals
SNDX
Price
$21.25
Change
+$5.05 (+31.17%)
Updated
Feb 3 closing price
Capitalization
1.85B
33 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NUVL vs SNDX

Header iconNUVL vs SNDX Comparison
Open Charts NUVL vs SNDXBanner chart's image
Nuvalent
Price$107.17
Change+$19.17 (+21.78%)
Volume$357.26K
Capitalization8.32B
Syndax Pharmaceuticals
Price$21.25
Change+$5.05 (+31.17%)
Volume$836.26K
Capitalization1.85B
NUVL vs SNDX Comparison Chart in %
NUVL
Daily Signal:
Gain/Loss:
SNDX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NUVL vs. SNDX commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Buy and SNDX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (NUVL: $107.17 vs. SNDX: $21.25)
Brand notoriety: NUVL and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 66% vs. SNDX: 58%
Market capitalization -- NUVL: $8.32B vs. SNDX: $1.85B
NUVL [@Biotechnology] is valued at $8.32B. SNDX’s [@Biotechnology] market capitalization is $1.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, both NUVL and SNDX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 6 TA indicator(s) are bullish while SNDX’s TA Score has 3 bullish TA indicator(s).

  • NUVL’s TA Score: 6 bullish, 3 bearish.
  • SNDX’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than SNDX.

Price Growth

NUVL (@Biotechnology) experienced а +0.68% price change this week, while SNDX (@Biotechnology) price change was -0.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

SNDX is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($8.32B) has a higher market cap than SNDX($1.85B). NUVL YTD gains are higher at: 6.541 vs. SNDX (1.142). SNDX has higher annual earnings (EBITDA): -282.58M vs. NUVL (-398.38M). NUVL has more cash in the bank: 943M vs. SNDX (454M). SNDX has higher revenues than NUVL: SNDX (111M) vs NUVL (0).
NUVLSNDXNUVL / SNDX
Capitalization8.32B1.85B451%
EBITDA-398.38M-282.58M141%
Gain YTD6.5411.142573%
P/E RatioN/AN/A-
Revenue0111M-
Total Cash943M454M208%
Total DebtN/A1.52M-
FUNDAMENTALS RATINGS
SNDX: Fundamental Ratings
SNDX
OUTLOOK RATING
1..100
59
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
5
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NUVLSNDX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 14 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
77%
Bearish Trend 8 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signal:
Gain/Loss:
SNDX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PNRZX86.963.41
+4.08%
PGIM Jennison Natural Resources Z
MLPLX6.440.13
+2.06%
Invesco SteelPath MLP Alpha Plus A
URITX33.310.13
+0.39%
Victory International R6
WFPAX46.620.09
+0.19%
Allspring Special Mid Cap Value A
HSUAX38.40-0.89
-2.27%
Rational Dynamic Brands A

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XNCR. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+2.12%
XNCR - NUVL
61%
Loosely correlated
-0.99%
CGON - NUVL
60%
Loosely correlated
-3.28%
RVMD - NUVL
59%
Loosely correlated
-1.22%
IDYA - NUVL
58%
Loosely correlated
+0.50%
XENE - NUVL
58%
Loosely correlated
+1.62%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with REPL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
-0.47%
REPL - SNDX
51%
Loosely correlated
+5.81%
CGON - SNDX
48%
Loosely correlated
-3.28%
ACLX - SNDX
47%
Loosely correlated
-0.01%
NUVL - SNDX
47%
Loosely correlated
+2.12%
IDYA - SNDX
46%
Loosely correlated
+0.50%
More